Prostate cancer is the third-most-common cancer in the world and ranked sixth in cancers fatal to men
Sanofi-Aventis SA, the world's third- biggest drugmaker, developed Taxotere treatment for advanced prostate cancer. It had a 21 percent lower death risk than those on another treatment.
(Taxotere generated 449 million euros ($606 million) in sales for Sanofi in the three months ended March 31, 10 percent more than a year earlier)
Successful cutting edge R&D for our quest for survival will generate revenue.
[Click here for full story at: BLOOMBERG.COM]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment